<DOC>
	<DOC>NCT02161107</DOC>
	<brief_summary>The purpose of this study is to determine whether it is safe to administer Grass-SPIRE to subjects suffering from both grass allergy and asthma</brief_summary>
	<brief_title>Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>Male or female, aged 1865 years. Asthma treated by inhaled SABA or inhaled SABA plus lowmedium dose ICS in 6 weeks prior to randomisation. A reliable history consistent with moderate to severe rhinoconjunctivitis on exposure to grass for at least the previous two grass seasons. Positive skin prick test to grass. Grassspecific Immunoglobulin E (IgE) â‰¥ 0.35 kU/L. History of lifethreatening asthma. Uncontrolled asthma according to GINA. FEV1 of &lt;70 % of predicted, regardless of the cause. Administration of adrenaline (epinephrine) is contraindicated (e.g. subjects with acute or chronic symptomatic coronary heart disease). History of severe drug allergy or anaphylactic reaction to food. A history of any significant disease or disorder (e.g. immune system, pulmonary, cardiovascular, gastrointestinal, liver, renal, neurological, metabolic, malignant, psychiatric, major physical impairment, history of alcohol or drug abuse)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Grass</keyword>
	<keyword>Allergy</keyword>
	<keyword>rhinoconjunctivitis</keyword>
	<keyword>rhinitis</keyword>
	<keyword>asthma</keyword>
</DOC>